Hematopoietic growth factor

Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update

Retrieved on: 
Wednesday, March 22, 2023
Biotechnology, Pharmaceutical, Health, Workforce, Febrile neutropenia, Quarter, Continuous operation, Spectrum Pharmaceuticals, Cancer, Research, Medication, Hematopoietic growth factor, Journal of the National Comprehensive Cancer Network, Patient, Risk, SPPI, Growth, FDA, Total, Spectrum, Video game, Cryptocurrency, Pharmaceutical industry

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022.

Key Points: 
  • Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022.
  • First launch quarter for ROLVEDON, with net sales for the quarter and year ended December 31, 2022, totaling $10.1 million.
  • Cash, cash equivalents and marketable securities of $75.1 million at December 31, 2022, giving us an expected runway through 2024.
  • The Company had a total cash, cash equivalents, and marketable securities balance of approximately $75.1 million at December 31, 2022.

Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, DSN, SPPI, Hematopoietic stem cell transplantation, Infection, FN, Health, Patient, Cancer, Pegfilgrastim, Research, Febrile neutropenia, Incidence, Medicine, NCCN, Maintenance, Medication, Policy, Journal of the National Comprehensive Cancer Network, Hematopoietic growth factor, Safety, Education, Spectrum Pharmaceuticals, BLA, Risk, Pharmaceutical industry, Neutropenia

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network Supportive Care Guidelines (NCCN Guidelines) in oncology for Hematopoietic Growth Factors.

Key Points: 
  • Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network Supportive Care Guidelines (NCCN Guidelines) in oncology for Hematopoietic Growth Factors.
  • The NCCN guidelines are a standard resource for determining the best course of treatment and supportive care for people living with cancer.
  • The inclusion in the NCCN guidelines further reinforces the clinical profile of ROLVEDON and is an important milestone for the program.
  • REDEFINING CANCER CARE and ROLVEDON are the Spectrum Pharmaceuticals logos and trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.